Loading…
Center for Instrumental Analysis of China Pharmaceutical University, a contract testing laboratory in Nanjing, China, was cited for significant deviations from Current Good Manufacturing Practice (CGMP) standards for active pharmaceutical ingredients (APIs) during an FDA inspection conducted in September 2024. The facility failed to maintain complete laboratory control records for API and intermediate testing, including inadequate documentation of Nuclear Magnetic Resonance (NMR) spectroscopy analysis results, with test records containing only unexplained numerical data without headers or clarifying information. These deficiencies rendered the tested APIs adulterated under the Federal Food, Drug, and Cosmetic Act, as the company's methods, facilities, and controls did not ensure compliance with established specifications and standards.